Following the discontinuation of batoclimab due to failed Phase 3 trials in thyroid eye disease, Roivant is fully prioritizing the development of IMVT-1402, a next-generation FcRn inhibitor, across multiple IgG-mediated autoimmune indications.

Expected impact: Establish IMVT-1402 as a best-in-class therapy for Graves' disease, Myasthenia Gravis, and other autoimmune conditions.

Preparing for the potential commercial launch of brepocitinib (TYK2/JAK1 inhibitor) in dermatomyositis while initiating a Phase 3 program in cutaneous sarcoidosis and enrolling a Phase 2b/3 trial in lichen planopilaris.

Expected impact: Generate first-in-class product revenues in dermatomyositis and expand the specialty dermatology/immunology franchise.

Advancing mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator in-licensed from Bayer, for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Expected impact: Address a high unmet medical need for ~200,000 patients in the U.S. and Europe with a potentially disease-modifying inhaled therapy.

Optimizing shareholder value by utilizing cash reserves and settlement proceeds to repurchase common shares.

Expected impact: Reduce outstanding share count and enhance long-term shareholder returns.